Compare ASPI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | PRME |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.3M | 536.4M |
| IPO Year | 2022 | 2022 |
| Metric | ASPI | PRME |
|---|---|---|
| Price | $4.28 | $3.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $12.00 | $7.56 |
| AVG Volume (30 Days) | ★ 3.9M | 2.7M |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,849,000.00 | $4,632,000.00 |
| Revenue This Year | $68.41 | $7.06 |
| Revenue Next Year | $126.69 | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | 55.28 |
| 52 Week Low | $3.51 | $2.67 |
| 52 Week High | $14.49 | $6.94 |
| Indicator | ASPI | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 49.07 |
| Support Level | $3.98 | $2.73 |
| Resistance Level | $5.88 | $3.60 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 85.79 | 72.27 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.